Clinical trial · Observational
Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada
Patients With Upper Gastrointestinal Adenocarcinoma Enrolled in a Patient Support Program to Receive Nivolumab in the Metastatic Setting: Real-World Data From Canada
NCT06361576CI-TRIAL-00075975completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when treated with nivolumab.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Upper Gastrointestinal Cancer | Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nivolumab | Drug | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Participants enrolled and treated with nivolumab in the metastatic setting
- interventionNames
- Drug: Nivolumab
Primary outcomes (6)
- measure
- Particpant sociodemographics
- timeFrame
- Baseline
- measure
- Participant Eastern Cooperative Oncology Group (ECOG) score
- timeFrame
- Baseline
- measure
- Participant HER2 status
- timeFrame
- Baseline
- measure
- Participant comorbidities
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Enrolled in the Bristol-Myers Squibb GastroEsophageal Opdivo in non-Resectable, advanced or metastatic Adenocarcinoma Patient Support Program (GEORgiA PsP) in Canada * Have consented to the use of their de-identified data generated from information collected during the course of the GEORgiA PsP Exclusion Criteria: * Aged \<18 years * HER2 positive status * Untreated brain metastases
References
Publications (0)
Data not yet available
No reference posted for this study.